Project Grant K08CA289948
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$298K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Boston, MA 02129, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $652,725 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a Phase I clinical trial of a novel cellular immunotherapy called CARV3.TEAM-E cells for the treatment of glioblastoma, a deadly brain cancer. The CARV3.TEAM-E cells are engineered CAR-T cells that secrete a T cell-engaging antibody molecule to more effectively target tumor...
This federal Project Grant award from the National Cancer Institute (under CFDA 93.395 - Cancer Treatment Research) provides $513,859 to the Dana-Farber Cancer Institute, Inc. in Boston, MA to develop a novel platform for persistent adoptive cellular therapy using hematopoietic stem cell (HSC)-derived chimeric antigen receptor (CAR)-expressing natural killer (NK) cells. The project aims to leverage naturally occurring NK-specific regulatory elements to restrict CAR expression to the NK cell...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,181,683 to the Dana-Farber Cancer Institute in Boston, MA to conduct research aimed at enhancing immune checkpoint blockade responsiveness and tertiary lymphoid structure formation through CD4+TFHx13 CAR-T cells to achieve cures for clear cell renal cell carcinoma (CCRCC).
The research will involve experimental design and computational analysis of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Sloan-Kettering Institute for Cancer Research to advance the development and translation of novel chimeric antigen receptor (CAR) T-cell therapies for solid tumors.
The key products or services to be delivered under this $1,313,806 award include:
Preclinical and clinical studies of CD28 costimulated CAR T-cells targeting the mesothelin antigen, with a focus on...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $680,594 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research on the novel regulation and functions of the TEAD-VGLL transcription factor complex. The key objectives are to: 1) characterize the structure and functions of the TEAD-VGLL3 complex, 2) investigate the role of TEAD-VGLL3 in resistance to TEAD inhibitors, and 3) develop new...
This $604,627 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Trustees of Dartmouth College aims to deconvolve the heterogeneity of chimeric antigen receptor (CAR) T cells to engineer durable antitumor immunity. The research will use dynamic lineage recording to analyze individual CAR T cell differentiation trajectories, determine the requirements for host and CAR T cell memory, and identify the effects of tumor burden and immune checkpoint...
This Project Grant award from the Defense Health Agency provides $979,875 to Dana-Farber Cancer Institute, Inc. for research under the Military Medical Research and Development program. The award aims to further optimize dual-targeted CAR T cells to achieve cures for advanced clear cell renal cell carcinoma (CCRCC) by fine-tuning CAR constructs against carbonic anhydrase IX and CD70 antigens based on tumor expression levels. Brigham and Women's Hospital, Inc. will receive a sub-award to...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is funding a research project to investigate mechanisms of immune therapy resistance. The $620,820 award to The General Hospital Corporation (Massachusetts General Hospital) supports studies to: 1) understand the molecular regulation and transcriptional effects of the CREB5 transcription factor, which was identified as a driver of immune evasion; 2) examine CREB5-interacting proteins...
This $400,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of next-generation chimeric antigen receptor T-cell (CAR-T) therapy for renal cell carcinoma (RCC). The project aims to evaluate whether the combination of two genetic modifications - PRDM1 exon 3 knockout and CTLA-4 cytoplasmic tail fusion - can enhance the anti-tumor activity of ENPP3-targeted CAR-T cells against RCC compared to either...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop a novel cancer immunotherapy strategy using genetically engineered B cells. The research aims to exploit homology-driven gene editing to generate tumor-specific B cells that can directly kill cancer cells and trigger robust anti-tumor T cell immunity. The project will evaluate the efficacy and tolerability of this B cell-based...